Acumen Pharmaceuticals, Inc. (ABOS) is a Biotechnology company in the Healthcare sector, currently trading at $2.68. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is ABOS = $7 (+161.2% upside).
Valuation: ABOS trades at a trailing Price-to-Earnings (P/E) of -1.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.11.
Net income is $121M (loss), growing at -45.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $31M against $70M equity (Debt-to-Equity (D/E) ratio 0.44, conservative). Current ratio is 4.07 (strong liquidity). Debt-to-assets is 25.5%. Total assets: $123M.
Analyst outlook: 7 / 7 analysts rate ABOS as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).
